Summary
Bristol Myers Squibb (BMY) filed its 2019 10-K on February 24, 2020, detailing its financial performance and strategic direction for the year ending December 30, 2019. A significant event during 2019 was the completion of the acquisition of Celgene, which is expected to be a transformative event for the company, bringing a strong portfolio of products in oncology and other therapeutic areas. This acquisition, along with ongoing research and development efforts, is central to BMY's future growth strategy. Investors should note the company's focus on integrating the Celgene business and realizing synergies, as well as managing the debt incurred to finance the acquisition. The report outlines various risks, including those related to the pharmaceutical industry's regulatory environment, competition, and intellectual property, as well as the successful commercialization of new products and the performance of existing blockbuster drugs. The company's ability to navigate these factors will be crucial for its long-term success.
Financial Highlights
57 data points| Revenue | $26.14B |
| Cost of Revenue | $8.08B |
| Gross Profit | $18.07B |
| R&D Expenses | $6.15B |
| SG&A Expenses | $4.87B |
| Operating Expenses | $21.17B |
| Interest Expense | $656.00M |
| Net Income | $3.44B |
| EPS (Basic) | $2.02 |
| EPS (Diluted) | $2.01 |
| Shares Outstanding (Basic) | 1.71B |
| Shares Outstanding (Diluted) | 1.71B |
Key Highlights
- 1Completion of the transformative acquisition of Celgene in the fourth quarter of 2019.
- 2Significant investment in research and development (R&D) to drive future growth, with a focus on oncology, immunology, and cardiovascular diseases.
- 3The company's portfolio is underpinned by key products such as Eliquis, Opdivo, and Revlimid (acquired through Celgene).
- 4Management's discussion and analysis (MD&A) likely details the strategic rationale and expected impact of the Celgene acquisition, including integration plans and synergy realization.
- 5The filing addresses various risks inherent in the pharmaceutical industry, including regulatory changes, patent expirations, competition, and pricing pressures.
- 6BMY is committed to managing its capital structure effectively, particularly in light of the debt financing for the Celgene acquisition.